OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy

详细信息    查看全文

• 作者：Ichiyo Shibahara ; Ryuta Saito ; Rong Zhang ; Masashi Chonan…
• 关键词：Glioblastoma ; OX40 ; OX40 ligand ; Immunotherapy ; Hypoxia ; Regulatory T cell
• 刊名：Molecular Cancer
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：14
• 期：1
• 全文大小：1,999 KB
• 参考文献：1. Stupp, R, Mason, WP, Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: pp. 987-96 CrossRef
  2. Johnson, LA, Sampson, JH (2010) Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr Neurol Neurosci Rep 10: pp. 259-66 CrossRef
  3. Rogers, PR, Song, J, Gramaglia, I, Killeen, N, Croft, M (2001) OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15: pp. 445-55 CrossRef
  4. Sugamura, K, Ishii, N, Weinberg, AD (2004) Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 4: pp. 420-31 CrossRef
  5. Ishii, N, Takahashi, T, Soroosh, P, Sugamura, K (2010) OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Adv Immunol 105: pp. 63-98 CrossRef
  6. Murata, K, Ishii, N, Takano, H, Miura, S, Ndhlovu, LC, Nose, M (2000) Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med 191: pp. 365-74 CrossRef
  7. Song, A, Tang, X, Harms, KM, Croft, M (2005) OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen. J Immunol 175: pp. 3534-41 CrossRef
  8. Weinberg, AD, Morris, NP, Kovacsovics-Bankowski, M, Urba, WJ, Curti, BD (2011) Science gone translational: the OX40 agonist story. Immunol Rev 244: pp. 218-31 CrossRef
  9. Croft, M (2010) Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 28: pp. 57-78 CrossRef
  10. Zaini, J, Andarini, S, Tahara, M, Saijo, Y, Ishii, N, Kawakami, K (2007) OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J Clin Invest 117: pp. 3330-8 CrossRef
  11. Andarini, S, Kikuchi, T, Nukiwa, M, Pradono, P, Suzuki, T, Ohkouchi, S (2004) Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res 64: pp. 3281-7 CrossRef
  12. Kjaergaard, J, Tanaka, J, Kim, JA, Rothchild, K, Weinberg, A, Shu, S (2000) Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 60: pp. 5514-21
  13. Weinberg, AD, Rivera, MM, Prell, R, Morris, A, Ramstad, T, Vetto, JT (2000) Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164: pp. 2160-9 CrossRef
  14. Piconese, S, Valzasina, B, Colombo, MP (2008) OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205: pp. 825-39 CrossRef
  15. Curti, BD, Kovacsovics-Bankowski, M, Morris, N, Walker, E, Chisholm, L, Floyd, K (2013) OX40 Is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 73: pp. 7189-98 CrossRef
  16. Weinberg, AD, Wegmann, KW, Funatake, C, Whitham, RH (1999) Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 162: pp. 1818-26
  17. Ohshima, Y, Tanaka, Y, Tozawa, H, Takahashi, Y, Maliszewski, C, Delespesse, G (1997) Expression and function of OX40 ligand on human dendritic cells. J Immunol 159: pp. 3838-48
  18
• 刊物主题：Cancer Research; Oncology;
• 出版者：BioMed Central
• ISSN：1476-4598

文摘

Background Glioblastoma is the most malignant human brain tumor and has a dismal prognosis; however, some patients show long-term survival. The interaction between the costimulatory molecule OX40 and its ligand OX40L generates key signals for T-cell activation. The augmentation of this interaction enhances antitumor immunity. In this present study, we explored whether OX40 signaling is responsible for antitumor adaptive immunity against glioblastoma and also established therapeutic antiglioma vaccination therapy. Methods Tumor specimens were obtained from patients with primary glioblastoma (n--10) and grade III glioma (n--4). Quantitative polymerase chain reaction (PCR), flow cytometry, and immunohistochemistry were used to analyze OX40L expression in human glioblastoma specimens. Functional consequences of OX40 signaling were studied using glioblastoma cell lines, mouse models of glioma, and T cells isolated from human subjects and mice. Cytokine production assay with mouse regulatory T cells was conducted under hypoxic conditions (1.5% O2). Results OX40L mRNA was expressed in glioblastoma specimens and higher levels were associated with prolonged progression-free survival of patients with glioblastoma, who had undergone gross total resection. In this regard, OX40L protein was expressed in A172 human glioblastoma cells and its expression was induced under hypoxia, which mimics the microenvironment of glioblastoma. Notably, human CD4 T cells were activated when cocultured in anti-CD3-coated plates with A172 cells expressing OX40L, as judged by the increased production of interferon-γ. To confirm the survival advantage of OX40L expression, we then used mouse glioma models. Mice bearing glioma cells forced to express OX40L did not die during the observed period after intracranial transplantation, whereas all mice bearing glioma cells lacking OX40L died. Such a survival benefit of OX40L was not detected in nude mice with an impaired immune system. Moreover, compared with systemic intraperitoneal injection, the subcutaneous injection of the OX40 agonist antibody together with glioma cell lysates elicited stronger antitumor immunity and prolonged the survival of mice bearing glioma or glioma-initiating cell-like cells. Finally, OX40 triggering activated regulatory T cells cultured under hypoxia led to the induction of the immunosuppressive cytokine IL10. Conclusion Glioblastoma directs immunostimulation or immunosuppression through OX40 signaling, depending on its microenvironment.